The combination with gemtuzumab in particular would be of interest for the core binding factor acute leukaemias given their success in the frontline setting (168).Combinations of PARP inhibitors with immunotherapy are particularly worthy of exploration given that hematologic toxicities with the latter are not as prominent as with cytotoxic chemotherapy. This evidence concerns the gene PARP1 and leukemia.